Takeda proposes sale of Shire drug to gain European approval
New Delhi: Takeda Pharmaceutical has proposed to European regulators it could sell a Shire treatment in development due to concerns of overlap in inflammatory bowel disease treatments and its own drug Entyvio as it seeks clearance for the two companies' merger.
The Japanese drug developer said it had proposed divesting Shire's pipeline compound SHP647, which is currently in Phase III clinical trials, along with some associated rights.
It said it did not expect the issue to delay its closing of the takeover of Shire and was the only issue it was discussing with European Union regulators after receiving approvals in China and Japan for the deal.
Read Also: Takeda gets Japan’s approval for $62 billion Shire purchase
bowel diseasechinaEntyvioEuropean approvalEuropean Union regulatorsJapanPhase III clinical trialsShire drugTakeda Pharma
Source : ReutersMedical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here
Next Story
NO DATA FOUND
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd